Back to results
US 2020/0048681 A1Published application
Antigen binding molecules and methods of use thereof
AssigneeKite Pharma, Inc.
InventorsJed Wiltzius, Stuart Sievers, Arianne Perez Garcia
Life of this patent
Estimating the term…
Abstract
Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GSTSGSGKPGSGEGSTKG (SEQ ID NO: 1), GSGKPGSGEG (SEQ ID NO: 2), GKPGSGEG (SEQ ID NO: 3), SGKPGSGE (SEQ ID NO: 499) and KPGSG (SEQ ID NO: 500) are provided. The antigen binding molecules can be used in the methods provided herein.
Claims22
A method of activating an immune cell expressing a molecule comprising an amino acid sequence selected from the group consisting of GSTSGSGKPGSGEGSTKG (SEQ ID NO:
- 1), GSGKPGSGEG (SEQ ID NO:
- 2), GKPGSGEG (SEQ ID NO:
- 3), SGKPGSGE (SEQ ID NO:
- 499) and KPGSG (SEQ ID NO:
- 500), the method comprising:
- (a) providing a sample comprising an immune cell known or suspected to be presenting a molecule comprising an amino acid sequence selected from the group consisting of GSTSGSGKPGSGEGSTKG (SEQ ID NO:
- 1), GSGKPGSGEG (SEQ ID NO:
- 2), GKPGSGEG (SEQ ID NO:
- 3), SGKPGSGE (SEQ ID NO:
- 499) and KPGSG (SEQ ID NO:
- 500);
- and
- (b) contacting an antigen binding molecule with the sample, under conditions that permit the formation of a binding complex comprising the antigen binding molecule and two molecules comprising the selected amino acid sequence, wherein the molecules comprising the selected amino acid sequences are disposed on two different immune cells,
- wherein the antigen binding molecule comprises:
- (i) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 7;
- (ii) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 8;
- (iii) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 9;
- (iv) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 13;
- (v) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 14;
- and
- (vi) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 15,
- or wherein the antigen binding molecule comprises:
- (vii) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 19;
- (viii) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 20;
- (ix) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 21;
- (x) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 25;
- (xi) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 26;
- and
- (xii) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 27.
38 more elements
The method of claim 5, wherein the T cell is disposed in vitro.
Dependencies are inferred from the claim text.